Her current position (since 2009) is CMDh member (EU-representative)/Policy adviser of the department Policy, Governance and Regulatory Affairs. Since May 2009 she is acting as Member and official representative in the CMDh on behalf of the MEB. She is member of several working parties of CMDh with issues related to (the new) Pharmacovigilance legislation (like RMPs/PSURs) as an area for special attention. She graduated MSc Pharmacy (in 1983) and as a pharmacist (in 1985).

Virginia (Ginny) has worked in industry and academia throughout her career, combining interests in science policy research and innovation performance within and across organizations. She joined MSD in 2017 to lead regulatory policy efforts ex-US for innovation that leads to better treatment for patients globally. Since 2020 this scope has expanded, as Ginny now leads the talented and experienced Global Regulatory Policy and Intelligence team for MSD. Her work has regularly focused on policy shocks that challenge innovation and access to novel therapies for patients, including global and industry-wide policy work on BREXIT, COVID-19 and now the R&D impacts of the Inflation Reduction Act.

Vicki, a qualified pharmacist, began her career in hospital pharmacy and later specialized in Drug Information Services, setting up Kuwait's first National Drug Information Centre. After returning to the UK and spending four years in community pharmacy, she transitioned to pharmacovigilance, joining Abbott as EU QPPV in 2005. She stepped down as AbbVie EU QPPV in 2018 due to Brexit. Now, as Head of PV Excellence and International QPPV, Vicki oversees the QPPV Office, Global Safety Compliance, and Risk Management. She is passionate about pharmacovigilance and developing teams.

Rita Purcell is the Deputy Chief Executive at the Health Products Regulatory Authority where she has responsibility for international affairs, finance, legal, regulatory affairs, corporate governance and infrastructure. She has lead on a number of international initiatives and is an active participant in the International Coalition of Medicines Regulatory Authorities (ICMRA). Rita is a member of the Board of the European Medicines Agency and has experience on other Boards and audit committees. She read law at University College Dublin and is qualified as a Chartered accountant. She previously worked for Price Waterhouse in Dublin and San Francisco and also has worked in the construction and food industries in the areas of finance